Affiliation:
1. Department of Pharmacology, Gifu University School of Medicine, Gifu 500,1
2. Department of Clinical Pharmacology, Graduate School of Pharmaceutical Sciences, The Tokushima University, Tokushima 770,2
3. Lederle Japan Ltd., Tokyo 175,3 and
4. Shitoro Clinic, Hamamatsu 432,4 Japan
Abstract
ABSTRACT
The pharmacokinetics and tolerability of a new parenteral carbapenem antibiotic, biapenem (L-627), were studied in healthy elderly volunteers aged 65 to 74 years (71.6 ± 2.7 years [mean ± standard deviation],
n
= 5; group B) and ≥75 years (77.8 ± 1.9 years,
n
= 5; group C), following single intravenous doses (300 and 600 mg), and compared with those of healthy young male volunteers aged 20 to 29 years (23.0 ± 3.5 years,
n
= 5; group A). The agent was well tolerated in all three age groups. Serial blood and urine samples were analyzed for biapenem to obtain key pharmacokinetic parameters by both two-compartment model-dependent and -independent methods. The maximum plasma concentration and area under plasma concentration-versus-time curve (AUC) increased in proportion to the dose in all three groups. Statistically significant age-related effects for AUC, total body clearance, and renal clearance (CL
R
) were found, while elimination half-life (
t
1/2β
) and percent cumulative recovery from urine of unchanged drug (% UR) remained unaltered (
t
1/2β
, 1.51 ± 0.42 [300 mg] and 2.19 ± 0.64 [600 mg] h [group A], 1.82 ± 1.14 and 1.45 ± 0.36 h [group B], and 1.75 ± 0.23 and 1.59 ± 0.18 h [group C]; %UR, 52.6% ± 3.0% [300 mg] and 53.1% ± 5.1% [600 mg] [group A], 46.7% ± 7.4% and 53.0% ± 4.8% [group B], and 50.1% ± 5.2% and 47.1% ± 7.6% [group C]). A significant linear correlation was observed between the CL
R
of biapenem and creatinine clearance at the dose of 300 mg but not at 600 mg. The steady-state volume of distribution tended to be decreased with age, although not significantly. Therefore, the age-related changes in parameters of biapenem described above were attributable to the combination of decreased lean body mass and lowered renal function of the elderly subjects. However, the magnitude of those changes does not necessitate dosage adjustment in elderly patients with normal renal function for their age.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference17 articles.
1. Adverse effects of monobactams and carbapenem.;Alvan G.;Drug Saf.,1995
2. Effects of age and gender on pharmacokinetics of cefepime
3. Pharmacokinetic studies in elderly people. Are they necessary?;Crome P.;Clin. Pharmacokinet.,1994
4. Crowley
J.
Echaves
S.
Cusak
B.
Vestal
R.
The elderly
Rational therapeutics: a clinical pharmacologic guide for the health professional.
Williams
R.
Brater
D.
Mordenti
J.
1990
141
174
Marcel Dekker Inc.
New York N.Y
5. Adult lean body mass declines with age: some longitudinal observations.;Forbes G. B.;Metabolism,1970
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献